| 0.4315 0.003 (0.58%) | 10-24 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.61 | 1-year : | 0.71 |
| Resists | First : | 0.52 | Second : | 0.61 |
| Pivot price | 0.47 |
|||
| Supports | First : | 0.38 | Second : | 0.32 |
| MAs | MA(5) : | 0.43 |
MA(20) : | 0.47  |
| MA(100) : | 0.52 |
MA(250) : | 0.69 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 7.9 |
D(3) : | 8 |
| RSI | RSI(14): 43 |
|||
| 52-week | High : | 1.59 | Low : | 0.37 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ PMN ] has closed above bottom band by 24.9%. Bollinger Bands are 33.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.45 - 0.45 | 0.45 - 0.45 |
| Low: | 0.41 - 0.41 | 0.41 - 0.42 |
| Close: | 0.43 - 0.43 | 0.43 - 0.43 |
ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
Wed, 22 Oct 2025
ProMIS Neurosciences (Nasdaq: PMN) names Ally Bridge's Slanix Paul Alex to board - Stock Titan
Wed, 22 Oct 2025
ProMIS Neurosciences Strengthens Board with Appointment of - GlobeNewswire
Mon, 20 Oct 2025
PMN Stock Price and Chart — NASDAQ:PMN - TradingView
Mon, 06 Oct 2025
Milbury Max a buys ProMis Neurosciences (PMN) shares worth $14928 - Investing.com
Mon, 06 Oct 2025
ProMIS Neurosciences Stock (PMN) Opinions on Alzheimer’s Candidate Fast Track Designation - Quiver Quantitative
Wed, 03 Sep 2025
Zero ARIA Cases: ProMIS's Novel Alzheimer's Drug PMN310 Advances to Final Trial Phase with Clean Safety Data - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 54 (M) |
| Shares Float | 32 (M) |
| Held by Insiders | 34.6 (%) |
| Held by Institutions | 24.5 (%) |
| Shares Short | 320 (K) |
| Shares Short P.Month | 52 (K) |
| EPS | -0.08 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.01 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -281.5 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.4 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -24 (M) |
| Levered Free Cash Flow | -12 (M) |
| PE Ratio | -6.17 |
| PEG Ratio | 0 |
| Price to Book value | -43.16 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.97 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|